Slide 1: Royalty Pharma
ROYALTY PHARMA
Slide 2: Imdelltra royalty acquisition
royalty acquisition August 2025
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by Royalty Pharma plc (the “Company”), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or
Slide 4: Key messages
Key messages 1 2 3 Imdelltra addresses high Transformative Phase 3 Rapid uptake and multi- unmet need in SCLC clinical results blockbuster potential Amgen’s Imdelltra, a first-in class targeted Imdelltra reduced risk of death by 40% vs. Rapid launch driven by Amgen with strong immunotherapy, receive
Slide 5: Acquired royalty on Amgen's Imdelltra for small cell lung cancer
Acquired royalty on Amgen’s Imdelltra for small cell lung cancer Amgen’s launch has outperformed consensus(1) (Imdelltra sales; $ in billions) • Up to $950m for portion of BeOne’s approved, uncapped royalty in Amgen’s Imdelltra for extensive-stage small cell lung cancer Consensus (current) $3.0 Cons
Slide 6: Imdelltra is transforming the SCLC treatment paradigm
Imdelltra is transforming the SCLC treatment paradigm Imdelltra OS benefit has impressive durability(1) SCLC treatment paradigm 100% Imdelltra Phase 2 (DeLLPhi-301) First-line First-line Second-line 90% Imdelltra Phase 3 (DeLLPhi-304) (limited-stage) (extensive-stage) (extensive-stage) SoC chemother
Slide 7: Royalty Pharma sees multi-blockbuster potential
Royalty Pharma sees multi-blockbuster potential RP sees significant commercial opportunity in the approved 2L+ SCLC indication with high conviction in first-line label expansion Extensive-stage 2L+ SCLC First-line SCLC Additional opportunities (Imdelltra approved) (Phase 3 studies ongoing) (Clinical
Slide 8: Imdelltra to enhance RP long-term growth and diversification
Imdelltra to enhance RP long-term growth and diversification Amgen’s Imdelltra is seeing rapid uptake(1) Consensus sales of >$2.8bn by 2035(1) (Imdelltra sales; $ in millions) (Imdelltra sales; $ in billions) Imdelltra U.S. sales $2.8 Imdelltra RoW sales $134 $2.6 $2.5 Imdelltra consensus sales (pre